TargetBeta
FLT3
fms related receptor tyrosine kinase 3 · also STK1, FLK2, CD135 · CD molecules
11 programs in company-led studies act on FLT3, from 10 companies: 7 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (11 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| jaktinibrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 318 running | JAK1, JAK2, JAK3 | the studies' text |
| AXL/FLT3/VEGFR2 Inhibitor KC1036rule | Beijing Konruns Pharmaceutical | phase 3 | 76 running | AXL, KDR | NCIt |
| quizartinibrule | Daiichi Sankyo | phase 3 | 225 running | CSF1R, KIT, PDGFRA, PDGFRB, RET | ChEMBL |
| flonoltinibrule | Chengdu Zenitar Biomedical Technology | phase 3 | 74 running | CDK6, JAK2 | the studies' text |
| pacritinibrule | Swedish Orphan Biovitrum | phase 3 | 183 running | ACVR1, IRAK1, JAK2 | NCIt |
| FLT3 Inhibitor XY0206rule | Shijiazhuang Yiling Pharmaceutical | phase 3 | 53 running | – | NCIt |
| gilteritinibrule | Astellas Pharma | phase 3 | 202 running | ALK, AXL, LTK | NCIt |
| Anti-FLT3/CD3 Bispecific Antibody CLN-049rule | Cullinan Therapeutics | phase 2 | 22 running | CD3E | NCIt |
| nefextinibrule | Maxinovel Pty. | phase 2 | 91 running | – | NCIt |
| flonoltinib maleaterule | Chengdu Zenitar Biomedical Technology | phase 2 | 21 running | JAK2 | NCIt |
| HPB-092rule | Hangzhou Polymed Biopharmaceuticals | phase 1 | 11 running | IRAK4 | the studies' text |
Also acted on by the same programs
Conditions their studies are in
- Leukemia, Myeloid, Acute, 6 programs
- COVID-19, 2 programs
- Primary Myelofibrosis, 2 programs
- Alopecia Areata, 1 program
- Carcinoma, Non-Small-Cell Lung, 1 program
- Colorectal Neoplasms, 1 program
- Dermatitis, Atopic, 1 program
- Esophageal Squamous Cell Carcinoma, 1 program
- Hematologic Neoplasms, 1 program
- Hodgkin Disease, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 30, 2026AXL/FLT3/VEGFR2 Inhibitor KC1036 · Beijing Konruns Pharmaceutical · phase 3 · NCT06194734
- Dec 30, 2026flonoltinib · Chengdu Zenitar Biomedical Technology · phase 3 · NCT07768111
- Dec 30, 2026pacritinib · Swedish Orphan Biovitrum · phase 3 · NCT06782373
- Feb 2027jaktinib · Suzhou Zelgen Biopharmaceuticals · phase 3 · NCT07565597
- May 1, 2027quizartinib · Daiichi Sankyo · phase 3 · NCT03793478
- Jun 2027HPB-092 · Hangzhou Polymed Biopharmaceuticals · phase 1 · NCT07137637
- Jul 1, 2027FLT3 Inhibitor XY0206 · Shijiazhuang Yiling Pharmaceutical · phase 3 · NCT05876832
- Sep 1, 2027nefextinib · Maxinovel Pty. · phase 2 · NCT07743112
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.